# Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women

> **NCT03201861** · PHASE3 · RECRUITING · sponsor: **RenJi Hospital** · enrollment: 762 (estimated)

## Conditions studied

- Tubular Breast Cancer
- Mucinous Breast Cancer
- Invasive Duct Carcinoma of Breast

## Interventions

- **DRUG:** Paclitaxel, Cisplatin
- **DRUG:** EC to docetaxel or paclitaxel

## Key facts

- **NCT ID:** NCT03201861
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-07-27
- **Primary completion:** 2027-08-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 762 (ESTIMATED)
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03201861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03201861, "Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03201861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*